Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Obesity is a prevalent global health issue affecting approximately half of the world's population.Extensive scientific research highlights the urgent need for effective obesity management to mitigate health risks and prevent complications.While bariatric surgery has proven to be highly effective, providing substantial short-term and long-term weight loss and resolution of obesity-related comorbidities, it is important to recognize its limitations and associated risks.Given the global obesity epidemic and the limitations of surgical interventions, there is high demand for effective and safe anti-obesity medications (AOMs).In Korea, the Korean Society for the Study of Obesity strongly advocates for the use of pharmacotherapy in Korean adults with a body mass index of 25 kg/m² or higher who have not achieved weight reduction through non-pharmacological treatments.Currently, five AOMs have been approved for long-term weight management: orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide.Tirzepatide is awaiting approval, and compounds such as CagriSema (Novo Nordisk) and oral semaglutide are currently undergoing rigorous evaluation in phase 3 clinical trials.Furthermore, other promising drugs, including orforglipron, BI 456906, and retartrutide, are progressing to phase 3 studies, expanding the therapeutic options for obesity management.In personalized patient care, physicians play a crucial role in accurately identifying individuals who genuinely require pharmacotherapy and selecting appropriate AOMs based on individual patient characteristics.By integrating evidence-based interventions and considering the unique needs of patients, healthcare professionals significantly contribute to the success of obesity management strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 The percentage of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% weight loss for each medication. Data were extracted from the following trials: XENical in the Prevention of Diabetes in Obese Subjects (XENDOS; orlistat),8 Contrave Obesity Research I (COR-I; naltrexone/bupropion [NB] extended-release [ER]),23 Satiety and Clinical Adiposity-Liraglutide (SCALE) Obesity and Prediabetes and its extension (liraglutide 3.0 mg),37,40 EQUIP (phentermine/topiramate [P/T] ER 1 year),49 SEQUEL (P/T ER 2 years),31 Semaglutide Treatment Effect in People with obesity (STEP) 1 (semaglutide 2.4 mg),13 and SURMOUNT-1 (tirzepatide 15 mg).48](https://figures.cochat.ai/paper-figures/506dbdfc48e84bddbe64b4302c180eb6/approved-anti-obesity-medications-in-2022-ksso-guidelines-and-the-promise-of-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-obesity medications have been approved by the U.S. Food and Drug Administration (FDA), including orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide, and tirzepatide, while newer agents such as orforglipron and retatrutide continue to emerge through late-phase trials [2,3,4,5,6,7].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orlistat was consistently associated with oily stools, fecal urgency, and flatulence with discharge, occurring in 15–30% of users [2,5,20]; fat soluble vitamin malabsorption and rare cases of gallstones, kidney stones, liver injury, and pancreatitis were noted as well.”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sympathomimetic agents such as phentermine and combinations like phentermine/topiramate or naltrexone/bupropion, produced fewer GI events overall.”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common effects were mild constipation, dry mouth, or dysgeusia [2,3,5].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Orlistat causes mechanism-specific adverse effects including steatorrhea, fecal urgency, and oily stools, due to fat malabsorption [2,5].”
From Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“Liraglutide shares a 97% amino acid sequence similarity with human GLP-1(7-37), with the substitution of lysine to arginine at position 34, and it also has palmitic acid conjugated via a glutamate spacer at lysine in position 26.”
BackgroundFuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Research works printed but not linked: 1
- Kim KK. Peptides in obesity treatment. Arch Obes Metab 2022;1:4-13.
Cited by
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
“Current guidelines recommend that, particularly for high-risk people with severe obesity or obesity-related complications, lifestyle programs can be combined with OMMs or metabolic bariatric surgery (MBS) 10–13 , with recent evidence suggesting that these interventions can be risk stratified 14,15 .”
Subramaniyan, V., & Hanim, Y. U. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01729-1 · Cited by 112
“However, when employing strategy-related pharma-cotherapy for obesity management, scientists and healthcare providers should adhere to several core guidelines [86].”
Pan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., et al. (2024) · Obesity · doi:10.1002/oby.24002 · Cited by 71
“Other studies have also reported similar results in which tirzepatide improved metabolic conditions of patients with mild to moderate adverse effects [76].”
ResultXie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension
Sioutas, G. S., Mualem, W., Reavey-Cantwell, J. F., & Rivet, D. J. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2020 · Cited by 59
Metadata
- Authors
- Jeon, E., Lee, K. Y., & Kim, K.-K.
- Affiliations
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University College of Medicine, Incheon, Korea
- Gachon University (KR)
- Corresponding author
- Kim, Kyoung-Kon
- Venue
- Journal of Obesity & Metabolic Syndrome
- Published
- 2023-06-23
- Volume
- 32
- Issue
- 2
- Pages
- 106-120
- ISSN
- 2508-6235 (ISSN-L)
- 2508-7576
- PMC
- PMC10327684
- OpenAlex
- W4381610885
- Cited by
- 39
- References
- 69
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 14 · 2023: 5
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- anti-obesity drugs, obesity pharmacotherapy, orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, tirzepatide, orforglipron, obesity treatment, drug approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. https://app.cochat.ai/papers/10.7570/jomes23032
- The paper
- Jeon, E., Lee, K. Y., & Kim, K.-K. (2023). Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. Journal of Obesity & Metabolic Syndrome. https://doi.org/10.7570/jomes23032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.